Novel Androgen Receptor Degrader for Androgenetic Alopecia (AGA) Application

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.